2HU0

N1 neuraminidase in complex with oseltamivir 1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.95 Å
  • R-Value Free: 0.295 
  • R-Value Work: 0.218 
  • R-Value Observed: 0.221 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

Russell, R.J.Haire, L.F.Stevens, D.J.Collins, P.J.Lin, Y.P.Blackburn, G.M.Hay, A.J.Gamblin, S.J.Skehel, J.J.

(2006) Nature 443: 45-49

  • DOI: 10.1038/nature05114
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Ta ...

    The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Neuraminidases from influenza type A viruses form two genetically distinct groups: group-1 contains the N1 neuraminidase of the H5N1 avian virus and group-2 contains the N2 and N9 enzymes used for the structure-based design of current drugs. Here we show by X-ray crystallography that these two groups are structurally distinct. Group-1 neuraminidases contain a cavity adjacent to their active sites that closes on ligand binding. Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs.


    Organizational Affiliation

    MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Neuraminidase
A, B, C, D, E, F, G, H
387Influenza A virusMutation(s): 1 
EC: 3.2.1.18
Find proteins for Q6DPL2 (Influenza A virus)
Go to UniProtKB:  Q6DPL2
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G39
Query on G39

Download CCD File 
B
(3R,4R,5S)-4-(acetylamino)-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
C14 H24 N2 O4
NENPYTRHICXVCS-YNEHKIRRSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
G39IC50:  0.30000001192092896   nM  BindingDB
G39Ki:  1.100000023841858   nM  BindingDB
G39IC50:  0.20000000298023224   nM  BindingDB
G39IC50:  1.2999999523162842   nM  BindingDB
G39IC50:  26   nM  BindingDB
G39Ki:  7.900000095367432   nM  BindingDB
G39IC50:  0.6000000238418579   nM  BindingDB
G39IC50:  1   nM  BindingDB
G39IC50:  3.700000047683716   nM  BindingDB
G39IC50:  0.4000000059604645   nM  BindingDB
G39IC50:  49   nM  BindingDB
G39IC50:  0.10000000149011612   nM  BindingDB
G39IC50:  1.7999999523162842   nM  BindingDB
G39IC50:  2.5999999046325684   nM  BindingDB
G39Ki:  4.900000095367432   nM  BindingDB
G39IC50:  0.7300000190734863   nM  BindingDB
G39IC50:  7.099999904632568   nM  BindingDB
G39IC50:  0.8999999761581421   nM  BindingDB
G39IC50:  4.900000095367432   nM  BindingDB
G39IC50:  11   nM  BindingDB
G39IC50:  1   nM  BindingDB
G39Ki:  0.10000000149011612   nM  BindingDB
G39IC50:  2.200000047683716   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.95 Å
  • R-Value Free: 0.295 
  • R-Value Work: 0.218 
  • R-Value Observed: 0.221 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 198.083α = 90
b = 200.576β = 90
c = 210.417γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
CrystalCleardata collection
CrystalCleardata reduction
CrystalCleardata scaling
AMoREphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2006-09-05
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Non-polymer description, Version format compliance